Table 3. Distribution of health-related quality of life profile in Asian prostate cancer patients receiving androgen deprivation therapy.

Measure		EQ-5D-5L utility index score			EQ-VAS score
		Median	IQR	p-value	Median	IQR	p-value
Baseline				<0.001			<0.001
	Overall (n=442)	0.924	0.876–1.000		80.0	70.0–90.0
	Hong Kong (n=239)	1.000	0.891–1.000		80.0	70.0–90.0
	China (n=72)	0.897	0.886–0.951		91.5	90.0–93.0
	Taiwan (n=75)	1.000	0.881–1.000		80.0	70.0–90.0
	Malaysia (n=56)	0.843	0.767–0.928		70.0	50.0–72.5
Month 6				<0.001			<0.001
	Overall (n=338)	0.936	0.886–1.000		80.0	75.0–90.0
	Hong Kong (n=204)	1.000	0.891–1.000		80.0	75.0–90.0
	China (n=44)	0.892	0.886–0.934		90.0	89.0–92.5
	Taiwan (n=47)	1.000	0.936–1.000		80.0	75.0–90.0
	Malaysia (n=43)	0.838	0.703–0.928		70.0	62.5–82.5
Month 12				0.001			0.001
	Overall (n=242)	0.933	0.849–1.000		80.0	70.0–90.0
	Hong Kong (n=178)	1.000	0.891–1.000		80.0	70.0–90.0
	China (n=17)	0.885	0.876–0.906		91.0	88.0–92.5
	Taiwan (n=33)	1.000	0.881–1.000		80.0	70.0–90.0
	Malaysia (n=14)	0.838	0.633–0.919		75.0	60.0–75.0

IQR: interquartile range, VAS: visual analog scale.